For example, inhibitors of HDAC have emerged as promising candidates to treat cognitive decline, and the FDA approved HDAC inhibitor Vorinostat is currently undergoing trials in Alzheimer's disease patients (ClinicalTrials.gov Identifier: NCT03056495). The gene discussed is HDAC9; the disease is early-onset autosomal dominant Alzheimer disease.